Skip to content

ASSURED PHARMACY, INC.: 10-Q filed 2013-11-14

What ASSURED PHARMACY, INC. reported in its quarterly report filed 2013-11-14 (fiscal Q3 2013): 30 published measures, 78 facts as tagged in accession 0001117768-13-000578.

This filing

Form
10-Q (quarterly report)
Filed
2013-11-14
Fiscal period
fiscal Q3 2013
Accession
0001117768-13-000578 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All ASSURED PHARMACY, INC. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2013-09-301,178,154USD
At 2012-12-312,221,498USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2013-09-3010,574,726USD
At 2012-12-318,708,571USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2013-09-30-9,396,572USD
At 2012-12-31-6,487,073USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2013-09-306,610USD
At 2012-12-3121,298USD
At 2012-09-306,165USD
At 2011-12-3123,316USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2013-07-01 to 2013-09-30-837,305USD92
2013-01-01 to 2013-09-30-3,817,840USD273
2012-07-01 to 2012-09-30-1,398,009USD92
2012-01-01 to 2012-09-30-3,524,461USD274

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2013-01-01 to 2013-09-30-1,228,909USD273
2012-01-01 to 2012-09-30-409,071USD274

Capital expenditure payments

Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.

PeriodValueUnitDays
2013-01-01 to 2013-09-3047,649USD273
2012-01-01 to 2012-09-3021,285USD274

Revenue

Revenue under this specific accounting concept. A missing value is not zero; filers can use other revenue concepts.

PeriodValueUnitDays
2013-07-01 to 2013-09-30926,551USD92
2013-01-01 to 2013-09-304,000,052USD273
2012-07-01 to 2012-09-301,494,718USD92
2012-01-01 to 2012-09-304,091,006USD274

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2013-01-01 to 2013-09-301,260,870USD273
2012-01-01 to 2012-09-30413,205USD274

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

PeriodValueUnitDays
2013-01-01 to 2013-09-30-46,649USD273
2012-01-01 to 2012-09-30-21,285USD274

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2013-09-30-46,881,708USD
At 2012-12-31-43,063,871USD

Income tax expense or benefit

Current and deferred income tax expense or benefit for continuing operations. This accounting expense differs from cash taxes paid.

PeriodValueUnitDays
2013-07-01 to 2013-09-3040,880USD92
2013-01-01 to 2013-09-30313,997USD273
2012-07-01 to 2012-09-30-17,549USD92
2012-01-01 to 2012-09-3018USD274

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

PeriodValueUnitDays
At 2013-09-3077,278USD
At 2012-12-3145,743USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2013-01-01 to 2013-09-30540,872USD273
2012-01-01 to 2012-09-30808,651USD274

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2013-09-30946,467USD
At 2012-12-311,255,583USD

Interest expense

Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.

PeriodValueUnitDays
2013-07-01 to 2013-09-30311,855USD92
2013-01-01 to 2013-09-30893,873USD273
2012-07-01 to 2012-09-30330,274USD92
2012-01-01 to 2012-09-301,033,250USD274

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2013-09-3010,285,601USD
At 2012-12-317,567,704USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2013-07-01 to 2013-09-30749,364USD92
2013-01-01 to 2013-09-303,103,399USD273
2012-07-01 to 2012-09-301,042,930USD92
2012-01-01 to 2012-09-303,109,895USD274

Gross profit

Revenue less the costs directly attributed to the goods or services sold. It precedes other operating expenses and is not net income.

PeriodValueUnitDays
2013-07-01 to 2013-09-30217,666USD92
2013-01-01 to 2013-09-30912,819USD273
2012-07-01 to 2012-09-30392,691USD92
2012-01-01 to 2012-09-30984,290USD274

Cost of revenue

Costs attributed to goods produced and sold and services provided during the period. This is not the sum of every operating expense.

PeriodValueUnitDays
2013-07-01 to 2013-09-30708,885USD92
2013-01-01 to 2013-09-303,087,233USD273
2012-07-01 to 2012-09-301,102,027USD92
2012-01-01 to 2012-09-303,106,716USD274

Selling, general and administrative expense

Selling and general administrative costs reported under this concept. It is an expense category, not a substitute for total operating expenses.

PeriodValueUnitDays
2013-07-01 to 2013-09-30303,938USD92
2013-01-01 to 2013-09-301,623,642USD273
2012-07-01 to 2012-09-30573,602USD92
2012-01-01 to 2012-09-301,768,973USD274

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2013-09-306,786,162shares
At 2012-12-314,476,846shares

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2013-09-3037,478,342USD
At 2012-12-3136,572,314USD

Long-term debt

Long-term borrowings under this concept, which can include the current portion depending on presentation. It is not total liabilities and may exclude leases and other obligations.

PeriodValueUnitDays
At 2013-09-307,770,406USD

Prepaid expenses and other current assets

Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.

PeriodValueUnitDays
At 2013-09-30383,815USD
At 2012-12-31135,021USD

Depreciation, depletion and amortization

Combined depreciation, depletion and amortization for the period. A noncash allocation of asset cost, not a measure of maintenance spending.

PeriodValueUnitDays
2013-01-01 to 2013-09-3029,756USD273
2012-01-01 to 2012-09-3024,231USD274

Income taxes paid, net

Cash income taxes paid net of refunds during the period. It differs from income tax expense and can reflect prior years and estimated payments.

PeriodValueUnitDays
2013-07-01 to 2013-09-3040,880USD92
2013-01-01 to 2013-09-30313,997USD273
2012-07-01 to 2012-09-30-17,549USD92
2012-01-01 to 2012-09-3018USD274

Proceeds from issuing common stock

Cash received from issuing common stock during the period. It is gross of costs only where the filer reports it so, and it does not include noncash issuances.

PeriodValueUnitDays
2013-01-01 to 2013-09-30860,000USD273

Change in accounts receivable

The cash flow adjustment for the change in receivables during the period. A positive value under this concept means receivables grew and reduced operating cash flow.

PeriodValueUnitDays
2013-01-01 to 2013-09-30404,490USD273
2012-01-01 to 2012-09-30-63,883USD274

Change in inventories

The cash flow adjustment for the change in inventories during the period. A positive value under this concept means inventory grew and reduced operating cash flow.

PeriodValueUnitDays
2013-01-01 to 2013-09-30143,686USD273
2012-01-01 to 2012-09-30185,781USD274

Inspect the source

Entity
ASSURED PHARMACY, INC. / CIK 0001100592
Captured
SEC response SHA-256
8754e2e6234cbfb53236c6fe79f2b449ee2f1bf8afde1f8141b3e08f86fb1dbe

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001100592.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))